Sodium-glucose cotransporter inhibitors may reduce the risk of pneumonia: an updated meta-analysis of cardiovascular outcome trials

The present meta-analysis included 8 cardiovascular outcome trials with 57,185 patients at high cardiometabolic risk. In comparison with placebo, treatment with sodium-glucose cotransporter inhibitors was associated with a significantly lower risk of pneumonia (RR 0.85, 95% CI 0.76–0.95, p = 0.004;...

Descripción completa

Detalles Bibliográficos
Autores principales: Barkas, Fotios, Anastasiou, Georgia, Milionis, Haralampos, Liberopoulos, Evangelos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179959/
https://www.ncbi.nlm.nih.gov/pubmed/34123693
http://dx.doi.org/10.1007/s13340-021-00515-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179959/
https://www.ncbi.nlm.nih.gov/pubmed/34123693
http://dx.doi.org/10.1007/s13340-021-00515-4

Ejemplares similares